Evren Alici

List of Publications by Year
in descending order

47 papers	1,928 citations	394421 19 h-index	254184 43 g-index
48 all docs	48 docs citations	48 times ranked	3388 citing authors

#	Article	IF	Citations
1	Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma. Cell Reports Medicine, 2022, 3, 100508.	6.5	20
2	NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals. Molecular Medicine, 2022, 28, 20.	4.4	18
3	Engineered NK Cells Against Cancer and Their Potential Applications Beyond. Frontiers in Immunology, 2022, 13, 825979.	4.8	14
4	Dynamic followâ€up of smoldering multiple myeloma identifies a subset of patients at high risk of progression. American Journal of Hematology, 2021, 96, E63-E65.	4.1	5
5	Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma. American Journal of Hematology, 2021, 96, 23-30.	4.1	5
6	Phosphodiesterase 4A confers resistance to PGE2â€mediated suppression in CD25⁺/CD54⁺ NK cells. EMBO Reports, 2021, 22, e51329.	4.5	8
7	Short-term IL-15 priming leaves a long-lasting signalling imprint in mouse NK cells independently of a metabolic switch. Life Science Alliance, 2021, 4, e202000723.	2.8	9
8	Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups. European Journal of Haematology, 2021, 106, 546-554.	2.2	1
9	Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14). American Journal of Hematology, 2021, 96, 925-933.	4.1	7
10	Predicting Drug Resistance by Single-Cell RNASeq in Patients with Multiple Myeloma. Clinical Chemistry, 2021, 67, 1309-1311.	3.2	2
11	Antibody response to <scp>COVID</scp>â€19 <scp>mRNA</scp> vaccine (<scp>Comirnaty</scp>) in myeloma patients treated with highâ€dose melphalan and/or immunotherapy. American Journal of Hematology, 2021, 96, E443-E446.	4.1	7
12	The Effect of Mesenchymal Stromal Cells Derived From Endometriotic Lesions on Natural Killer Cell Function. Frontiers in Cell and Developmental Biology, 2021, 9, 612714.	3.7	1
13	Outcome of COVIDâ€19 in multiple myeloma patients in relation to treatment. European Journal of Haematology, 2020, 105, 751-754.	2.2	17
14	Generation of Retinal Pigment Epithelial Cells Derived from Human Embryonic Stem Cells Lacking Human Leukocyte Antigen Class I and II. Stem Cell Reports, 2020, 14, 648-662.	4.8	35
15	Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D. Frontiers in Immunology, 2020, 11, 40.	4.8	40
16	CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. Journal of Clinical Investigation, 2020, 130, 1185-1198.	8.2	139
17	Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells. Journal of Clinical Investigation, 2020, 130, 5508-5522.	8.2	52
18	Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?. European Journal of Haematology, 2019, 103, 588-596.	2.2	24

#	Article	IF	Citations
19	Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma. European Journal of Haematology, 2019, 103, 247-254.	2.2	11
20	Characterization of human natural killer cells for therapeutic use. Cytotherapy, 2019, 21, 315-326.	0.7	5
21	Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. PLoS ONE, 2019, 14, e0211927.	2.5	85
22	Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells. Cancers, 2019, 11, 69.	3.7	21
23	Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples. Blood, 2019, 134, 1848-1848.	1.4	0
24	Lenalidomide versus lenalidomideÂ+Âdexamethasone prolonged treatment after secondâ€line lenalidomideÂ+Âdexamethasone induction in multiple myeloma. Cancer Medicine, 2018, 7, 2256-2268.	2.8	1
25	Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial. Cancer Chemotherapy and Pharmacology, 2018, 81, 183-193.	2.3	16
26	The Role of CXC Chemokine Receptors 1â€“4 on Immune Cells in the Tumor Microenvironment. Frontiers in Immunology, 2018, 9, 2159.	4.8	158
27	Perforin Promotes Amyloid Beta Internalisation in Neurons. Molecular Neurobiology, 2017, 54, 874-887.	4.0	17
28	Disclosing the Parameters Leading to High Productivity of Retroviral Producer Cells Lines: Evaluating Random Versus Targeted Integration. Human Gene Therapy Methods, 2017, 28, 78-90.	2.1	4
29	Direct evidence for a polygenic etiology in familial multiple myeloma. Blood Advances, 2017, 1, 619-623.	5.2	15
30	Independent control of natural killer cell responsiveness and homeostasis at steady-state by CD11c+ dendritic cells. Scientific Reports, 2016, 6, 37996.	3.3	18
31	Wnt/Î²-Catenin Stimulation and Laminins Support Cardiovascular Cell Progenitor Expansion from Human Fetal Cardiac Mesenchymal Stromal Cells. Stem Cell Reports, 2016, 6, 607-617.	4.8	20
32	Reâ€challenging with antiâ€CD38 monotherapy in tripleâ€refractory multiple myeloma patients is a feasible and safe approach. British Journal of Haematology, 2016, 174, 473-477.	2.5	19
33	Proteasome inhibitors and <scp>IM</scp>iDs can overcome some highâ€risk cytogenetics in multiple myeloma but not gain 1q21. European Journal of Haematology, 2016, 96, 46-54.	2.2	35
34	Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. Frontiers in Immunology, 2015, 6, 605.	4.8	153
35	The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex. Blood, 2015, 126, 3047-3047.	1.4	1
36	Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma. PLoS ONE, 2015, 10, e0138248.	2.5	7

#	Article	IF	Citations
37	Characterization of Stem-Like Cells in Mucoepidermoid Tracheal Paediatric Tumor. PLoS ONE, 2014, 9, e107712.	2.5	2
38	Up-regulation of DNAM-1 and NKp30, associated with improvement of NK cells activation after long-term culture of mononuclear cells from patients with ovarian neoplasia. Human Immunology, 2014, 75, 777-784.	2.4	11
39	The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment. PLoS ONE, 2014, 9, e101819.	2.5	49
40	GMP Facilities for Manufacturing of Advanced Therapy Medicinal Products for Clinical Trials: An Overview for Clinical Researchers. Current Gene Therapy, 2010, 10, 508-515.	2.0	15
41	Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy, 2010, 12, 1044-1055.	0.7	112
42	IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers. Current Opinion in Molecular Therapeutics, 2010, 12, 724-33.	2.8	24
43	Retroviral Gene Transfer into Primary Human Natural Killer Cells. Methods in Molecular Biology, 2009, 506, 127-137.	0.9	11
44	NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunology, Immunotherapy, 2008, 57, 1541-1552.	4.2	74
45	Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood, 2008, 111, 3155-3162.	1.4	171
46	Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model. Experimental Hematology, 2007, 35, 1839-1846.	0.4	47
47	Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma. Experimental Hematology, 2004, 32, 1064-1072.	0.4	30